Sign inJoin waitlistJoin the waitlist

Gregory Gan

Associate Professor, Radiation Oncology · University of Kansas School of Medicine

Credentials: · · · · · ·

History

University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present

Radiation Oncology
University of Colorado School of Medicine
2010–2014
UPMC
2009–2010
University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine
2005–2009

Research

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
Journal of Thoracic Oncology · 2012 · 563 citations
Unexplored therapeutic opportunities in the human genome
Review · Nature Reviews Drug Discovery · 2018 · 269 citations
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer…
International journal of radiation oncology · 2014 · First of 7 authors · Corresponding · 185 citations

Christopher Lominska
13 papers
Andrés Bur
8 papers
Antonio Jimeno
8 papers
Kiran Kakarala
8 papers
Yelizaveta Shnayder
8 papers
KB
Kiersten Berggren
7 papers
DR
David Raben
6 papers
Brian Kavanagh
5 papers
EY
Emrullah Yilmaz
5 papers
Prakash Neupane
5 papers
Ronald Chen
5 papers
Sana Karam
5 papers · 1 as a resident

Grants

The Role of MK2 on Head and Neck Cancer Cell Migration, Invasion, and Metastases
National Institute of Dental and Craniofacial Research · R01
Contact PI · $693.4K · University of Kansas Medical Center
2026–2031
Use of Apatinib-Nanosponge Conjugate to Reduce Post-Radiation Induced Oral Cavity and Salivary Fibrosis.
National Institute of Dental and Craniofacial Research · R41
PI · $298.9K · Deltamed Llc
2025–2026
The Kansas Institute for Precision Medicine
National Institute of General Medical Sciences · P20
Project lead · $459K · University of Kansas Medical Center
2019–2024
DNA Polymerase Zeta and Its Role in DNA Damage Tolerance
National Institute of Environmental Health Sciences · F30
Contact PI · $208.3K · University of Pittsburgh at Pittsburgh
2004–2009

Clinical trials

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
Principal investigator · Withdrawn · Phase 1
University of Kansas Medical Center
2024
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
Principal investigator · Completed · Phase 2
University of Kansas Medical Center
2020–2021